Merck Buy Rating Reiterated as sac-TMT Data De-Risk Oncology Pipeline; 12-Month Price Target Maintained at $137

TIPRANKS07-16 16:05

Goldman Sachs analyst Asad Haider maintained a Buy rating on Merck & Company yesterday and set a price target of $137.00. Asad Haider has given his...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment